Novartis real-world data at AAN confirms benefit of Gilenya ® on four key measures of disease activity in relapsing MS

Novartis today announced data from the Phase IV Multiple Sclerosis and clinical outcome and MRI in the US (MS-MRIUS) study, which confirmed the effectiveness of Gilenya® (fingolimod) in the real-world setting, supporting previous findings from Phase III trials[1],[2].
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news